Innovative, advanced therapies have enormous promise, but also come with a host of logistical problems that innovators underestimate at their own peril.
Validating the regulatory expectations on evidential requirements for predictive biomarkers is not a trivial process, but quite conceptually challenging.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
